Disclosure Of Interests In Other Entities [Text Block]
| Concept |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
As at 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
2023-01-01 to 2023-12-31 |
As at 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
2022-01-01 to 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Disclosure of interests in other entities [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of interests in subsidiaries [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of subsidiaries [text block] | — |
und ihre 100%igen Tochtergesellschaften Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, und Biofrontera Neuroscience GmbH,
|
— | — | — | — | — | — | — | — | — | — |
| Disclosure of subsidiaries [abstract] | ||||||||||||
| Disclosure of subsidiaries [line items] | ||||||||||||
| Current assets | — | — |
17,720
EUR
|
— | — | — |
15,056
EUR
|
— | — | — | — | — |
| Non-current assets | — | — |
13,012
EUR
|
— | — | — |
17,669
EUR
|
— | — | — | — | — |
| Current liabilities | — | — |
10,073
EUR
|
— | — | — |
8,387
EUR
|
— | — | — | — | — |
| Non-current liabilities | — | — |
678,000
EUR
|
— | — | — |
4,002
EUR
|
— | — | — | — | — |
| Revenue | — |
32,249
EUR
|
— | — | — | — | — | — |
25,738
EUR
|
— | — | — |
| Profit (loss) |
0
EUR
|
369,000
EUR
|
— |
0
EUR
|
369,000
EUR
|
0
EUR
|
— | — |
44,166
EUR
|
44,166
EUR
|
0
EUR
|
0
EUR
|
| Comprehensive income |
0
EUR
|
368,000
EUR
|
— |
0
EUR
|
369,000
EUR
|
1,000
EUR
|
— |
0
EUR
|
44,166
EUR
|
44,166
EUR
|
0
EUR
|
0
EUR
|
| Disclosure of interests in associates [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of associates [text block] | — |
Die Finanzanlagen beinhalten den Beteiligungsbuchwert der Biofrontera Inc. in Höhe von 1.718 TEUR (Vorjahr: 8.982 TEUR), die nach der At-Equity-Methode in den Konzernabschluss einbezogen und bewertet wird:
|
— | — | — | — | — | — | — | — | — | — |
| Disclosure of associates [abstract] | ||||||||||||
| Disclosure of associates [line items] | ||||||||||||
| Other comprehensive income |
0
EUR
|
1,000
EUR
|
— |
0
EUR
|
0
EUR
|
1,000
EUR
|
— |
0
EUR
|
0
EUR
|
0
EUR
|
0
EUR
|
0
EUR
|
| Investments accounted for using equity method | — | — |
1,718
EUR
|
— | — | — |
8,982
EUR
|
— | — | — | — | — |
| Disclosure of interests in joint arrangements [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of joint ventures [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of joint ventures [abstract] | ||||||||||||
| Disclosure of joint ventures [line items] | ||||||||||||
| Cash and cash equivalents | — | — |
3,080
EUR
|
— | — | — |
6,376
EUR
|
— | — | — | — | — |
| Other current financial liabilities | — | — |
71,000
EUR
|
— | — | — |
26,000
EUR
|
— | — | — | — | — |
| Interest income | — |
21,000
EUR
|
— | — | — | — | — | — |
1,000
EUR
|
— | — | — |
| Interest expense | — |
15,000
EUR
|
— | — | — | — | — | — |
163,000
EUR
|
— | — | — |
| Tax expense (income) | — |
1,758
EUR
|
— | — | — | — | — | — |
956,000
EUR
|
— | — | — |
| Disclosure of investment entities [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Disclosure of effect of change of investment entity status on financial statements [text block] | — | — | — | — | — | — | — | — | — | — | — | — |
| Gain (loss) on cessation of consolidation of subsidiaries due to change of investment entity status | — | — | — | — | — | — | — |
0
EUR
|
0
EUR
|
0
EUR
|
0
EUR
|
0
EUR
|